Featured Content

In a program supported by Verity Pharmaceuticals, E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology and Professor of Urology at the University of California, San Diego; Neal D. Shore, MD, FACS, Medical Director for the Carolina Urologic Research Center; and Benjamin H. Lowentritt, MD, FACS, Director of Prostate Cancer Services for United Urology Group discuss androgen deprivation therapy (ADT) as a foundational therapy for prostate cancer. They discuss managing testosterone (T) levels, adherence to T dosing schedules, and castrate-resistant prostate cancer (CRPC).

In a program supported by Verity Pharmaceuticals, E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology and Professor of Urology at the University of California, San Diego, discusses reinforcing consistent testosterone suppression in ADT and the role of triptorelin with Scott B. Sellinger, MD, President of Advanced Urology Institute and a Partner at Southeastern Urological Center in Tallahassee, Florida, and Paul R. Sieber, MD, FACS, President of Keystone Urology Specialists in Lancaster, Pennsylvania.